Evidence map›Paper›PMID 41301114›Full record

ArticleBioengineering (Basel, Switzerland)2025

Extracorporal Ovary Bioreactor System with Oxygen Supply and Drug Delivery Option.

Karin Bundschu, Sabine Eberhart, Florian Maiss, Isabella Milic, Martin Hessling

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Karin BundschuDepartment of Gynaecology and Obstetrics, University Hospital Ulm, Prittwitzstr. 43, 89075 Ulm, Germany.ORCID 0000-0001-9329-8958
Sabine EberhartDepartment of Gynaecology and Obstetrics, University Hospital Ulm, Prittwitzstr. 43, 89075 Ulm, Germany.
Florian MaissInstitute of Medical Engineering and Mechatronics, Ulm University of Applied Sciences (Technische Hochschule Ulm), Albert-Einstein-Allee 55, 89081 Ulm, Germany.
Isabella MilicInstitute of Medical Engineering and Mechatronics, Ulm University of Applied Sciences (Technische Hochschule Ulm), Albert-Einstein-Allee 55, 89081 Ulm, Germany.
Martin HesslingInstitute of Medical Engineering and Mechatronics, Ulm University of Applied Sciences (Technische Hochschule Ulm), Albert-Einstein-Allee 55, 89081 Ulm, Germany.ORCID 0000-0002-4859-2864

Funding

BMFTR FKZ 01GR2301
6 · The paper itself

Abstract

Young women who have survived cancer may have lost their fertility due to cytotoxic treatments like chemotherapy or irradiation. So far, oocyte or ovarian tissue cryopreservation are well-known and well-used opportunities for fertility preservation prior cytotoxic therapies. However, these methods are not possible in certain cases, like those with a high risk of ovarian metastasis or prepubertal girls. Therefore, new medical and biotechnological options are also being sought to help this patient group to fulfill their desire to have their own biological children. The investigation described here focuses on the possibility of in vitro follicle maturing. To this point, a long-term temperature and pH-controlled bioreactor system is developed that can supply a whole ovary with oxygen and nutrients over several days and offers the possibility of hormone administration or the delivery of other drugs. This bioreactor was then tested with mature bovine ovaries. After appropriate cannulation, antithrombotic vascular perfusion, and antibiotic pretreatment, the ovaries were cultured for up to 9 days without any contamination or suffering major vital cell damage. The controlled application of oocyte stimulation hormones (human menopausal gonadotropin; hMG) also enabled successful in vitro follicle growth and maturation. From a technical point of view, there is still optimization potential for this bioreactor system, but in principle, it has been demonstrated that long-term ovary cultivation and in vitro maturation of follicles are possible, which opens up further potential for these and other applications.

Indexed as

bovine ovarydrug delivery systemfollicle maturationlong-time cultivationperfusion bioreactor

Identifiers

PMID41301114
PMCPMC12649719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.